11 results about "Receptor binding sites" patented technology

The disclosure generally relates to binding proteins that comprise antigen binding sites, a T cell receptor binding site, and a T cell co-stimulatory molecule binding site. The disclosure also provides compositions comprising such binding proteins and nucleic acid molecules encoding such binding proteins. The disclosure further relates to methods of treating a disorder or condition using such binding proteins.

The disclosure generally relates to binding proteins that comprise antigen binding sites, a T cell receptor binding site, and a T cell co-stimulatory molecule binding site. The disclosure also relates to pharmaceutical compositions comprising such binding proteins, nucleic acid molecules encoding such binding proteins, and vectors comprising such nucleic acid molecules. The disclosure further relates to methods of treating a disorder or condition using such binding proteins and pharmaceutical compositions, binding proteins and pharmaceutical compositions for use in the treatment of a disorder or condition, and the use of such binding proteins and pharmaceutical compositions for the manufacture of a medicament for treating a disorder or condition.

The description generally relates to binding proteins comprising antigen-binding sites, a T-cell receptor-binding site, and a T-cell costimulatory molecule-binding site. The description also relates to pharmaceutical compositions comprising such binding proteins, nucleic acid molecules encoding such binding proteins, and vectors comprising such nucleic acid molecules. The description further relates to methods for treating a disorder or condition using such binding proteins and pharmaceutical compositions, binding proteins and pharmaceutical compositions for use in the treatment of a disorder or condition, and the use of such binding proteins and pharmaceutical compositions for the manufacture of a medicament to treat a disorder or condition.

The disclosure generally relates to binding proteins that comprise antigen binding sites, a T cell receptor binding site, and a T cell co-stimulatory molecule binding site. The disclosure also relates to pharmaceutical compositions comprising such binding proteins, nucleic acid molecules encoding such binding proteins, and vectors comprising such nucleic acid molecules. The disclosure further relates to methods of treating a disorder or condition using such binding proteins and pharmaceutical compositions, binding proteins and pharmaceutical compositions for use in the treatment of a disorder or condition, and the use of such binding proteins and pharmaceutical compositions for the manufacture of a medicament for treating a disorder or condition.

Provided herein are antibody construct molecules comprising (i) an Fc receptor binding site, (ii) an antigen-binding site and (iii) a spacer moiety located between (i) and (ii), wherein the spacer moiety serves to increase the distance between (i) and (ii) so as to reduce the agonistic activity of the molecule as compared to the antibody variant that lacks (iii). Disclosed are various antibodies that can be de-agonized by introduction of the spacer moiety. Of specific interest are agonistic check point targeting antibodies that are de-agonized by introduction of the spacer moiety.

The present invention discloses a novel anti-pulmonary fibrosis neutralizing antibody and a drug, belonging to the field of antibody drug preparation. Based on cutting-edge artificial intelligence technologies such as Alphafold and de novo protein design, the present invention designs a neutralizing antibody targeting the binding site of Gremlin2 and TGF-β receptor 1, prepares the antibody using genetic engineering techniques, inserts the gene fragment of the target antibody into a plasmid through in vitro recombination, and then transfers the edited plasmid into a cell line and performs in vitro amplification and culture of the cell line to obtain transcription and translation of the gene fragment in vitro, thereby preparing the antibody. The artificial intelligence method adopted by the present invention for designing the neutralizing antibody is efficient and reliable, the process for preparing the neutralizing antibody is simple, the neutralizing antibody has high homogeneity, is safe and effective, has a good anti-pulmonary fibrosis function in animal models, and has the potential for clinical treatment of pulmonary fibrosis.

The present disclosure relates generally to binding proteins comprising an antigen binding site, a T cell receptor binding site, and a T cell costimulatory molecule binding site. The disclosure also relates to pharmaceutical compositions comprising such binding proteins, nucleic acid molecules encoding such binding proteins and vectors comprising such nucleic acid molecules. The disclosure also relates to methods of treating a disorder or condition using such binding proteins and pharmaceutical compositions, binding proteins and pharmaceutical compositions for use in the treatment of a disorder or condition, and the use of such binding proteins and pharmaceutical compositions for the manufacture of a medicament for the treatment of a disorder or condition.

The present invention relates to chimeric GT-B type glycosyltransferases, comprising an N-terminal acceptor binding site, a C-terminal donor binding site, and a linker loop linking the N-terminal acceptor binding site and the C-terminal donor binding site, wherein (i) the N-terminal acceptor binding site domain comprises or consists of an amino acid sequence having at least 80 %, preferably at least 90 %, more preferably 100 % sequence identity to the amino acid sequence set forth in SEQ ID NO: 1; and / or (ii) the linker loop comprises or consists of an amino acid sequence having at least 80 %, preferably at least 90 %, more preferably 100 % sequence identity to the amino acid sequence set forth in SEQ ID NO: 4; and / or (iii) the C-terminal donor binding site domain comprises or consists of an amino acid sequence having at least 80 %, preferably at least 90 %, more preferably 100 % sequence identity to the amino acid sequence set forth in SEQ ID NO: 2 or comprises or consists of an amino acid sequence having at least 80 %, preferably at least 90 %, more preferably 100 % sequence identity to the amino acid sequence set forth in SEQ ID NO: 3; and / or (iv) the C-terminal donor binding site domain is a chimeric C-terminal donor binding site domain comprising a first amino acid sequence derived from a glycosyltransferase distinct from the glycosyltransferase from which the N-terminal acceptor binding site domain is derived, and a second amino acid sequence derived from the same glycosyltransferase as the N-terminal acceptor binding site domain, wherein the first amino acid sequence is linking the linker loop and the second amino acid sequence; to nucleic acid molecules encoding such GT-B type glycosyltransferases; to a method of production of such chimeric GT-B type glycosyltransferases; to a method of production of polysaccharides using such chimeric GT-B type glycosyltransferases and the polysaccharides obtainable by such a method; to polysaccharides defined by formula (I); to compositions comprising such polysaccharides; and further to uses of such polysaccharides as thickening and / or gelling agents and / or as rheology modifiers and / or as 3D-printing inks and / or coatings.

The present invention relates to the pharmaceutical field, specifically to the use of bile acids and animal bile products in the preparation of tumor radiosensitizers. By examining the docking characteristics of bile acids with the EphA2 receptor binding site, their inhibitory effects on EphA2 enzyme activity, their inhibitory effects on EphA2 phosphorylation, and their radiosensitization effects on radiotherapy-resistant tumor cells, it was found that bile acids, including taurocholic acid, ursodeoxycholic acid, and tauroursodeoxycholic acid, can inhibit EphA2 enzyme activity and EphA2 phosphorylation within the nanomolar to micromolar concentration range, and can inhibit radioresistance induced by elevated EphA2 expression and / or EphA2 phosphorylation within the micromolar concentration range. Therefore, bile acids, taurocholic acid, ursodeoxycholic acid, and tauroursodeoxycholic acid have promising application as tumor radiosensitizers.

The invention discloses a novel anti-pulmonary fibrosis neutralizing antibody and a medicine, and belongs to the field of antibody medicine preparation. Based on advanced artificial intelligence technologies such as Alphafold and protein de novo design, a neutralizing antibody targeting a binding site of Gremlin2 and a TGF-beta receptor 1 is designed, the antibody is prepared by utilizing a genetic engineering technology, gene segments of the target antibody are inserted into plasmids through in-vitro recombination, and the target antibody is obtained. And transferring the edited plasmid into a cell line and carrying out in-vitro amplification and culture on the cell line to obtain transcription and translation of a gene segment in vitro so as to prepare the antibody. The artificial intelligence method adopted by the invention is efficient and reliable in design of the neutralizing antibody, the flow process for preparing the neutralizing antibody is simple, the neutralizing antibody is high in homogeneity, safe and effective, has a better anti-pulmonary fibrosis function in an animal model, and has the potential for clinically treating pulmonary fibrosis.

The present disclosure is directed to individual peptide immunogen constructs targeting portions of the Interleukin-6 (IL-6) protein, compositions containing the constructs, antibodies elicited by the constructs, and methods for making and using the constructs and compositions thereof. The disclosed IL-6 peptide immunogen constructs contain a B cell epitope from IL-6 linked to a heterologous T helper cell (Th) epitope directly or through an optional heterologous spacer. The IL-6 peptide immunogen constructs stimulate the generation of highly specific antibodies directed to the IL-6 receptor (IL-6R) binding site for the prevention and / or treatment of diseases impacted by IL-6 dysregulation.